Results
anxiety, sleep behavior disorder, treatment-resistant rem sleep behavior disorder, PD-RBD, SD, dizziness, RBD, sleep-related injuries
Out of the 82 screened subjects, 58 were excluded: 33 were not eligible due to not meeting inclusion criteria on episode frequency (Baseline Characteristics. Intention-to-Treat Analysis in 24 Participants. BMI, body-mass index; No, number; RBD, rapid-eye-movement sleep behavior disorder; SD, standard deviation.Flow of patients through the trial of sodium oxybate in treatment-resistant rem sleep behavior disorder. Two patients receiving sodium oxybate withdrew from the study during the titration period due to dizziness and severe anxiety. No placebo-treated patients discontinued study drug.Both groups included 75% of males, all white, and an equal proportion of iRBD and PD-RBD. Average RBD symptom duration was 9.8 (5.8) years. Twenty-two participants had a history of sleep-related injuries. One-third of participants in each group (